Clinical trial
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With…
NCT00104650 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00104650 |
|---|---|
| Title | Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates |
| Official title | A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma |
| Intervention type | Drug, Genetic |
| Interventions | AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks |
| Enrollment | 111 |
| Start date | Jan 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Mar 1, 2010 |
| First posted | Mar 4, 2005 |
| Last update posted | Jan 24, 2011 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: